Penpulimab-Kcqx: Dosage Form, Projected Sales, NCE-1 Date | Penpulimab-Kcqx

Penpulimab-Kcqx

Penpulimab‑Kcqx is an intravenous PD‑1 inhibitor used with chemotherapy to treat recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It boosts immune response to help control tumor growth in patients who have progressed after prior therapies.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Penpulimab-Kcqx
Innovator :

AKESO BIOPHARMA CO., LTD
Approval Date :

23-Apr-25
Data Exclusivity Expiry :

23-Apr-29
Market Exclusivity Expiry :

23-Apr-37
Dosage Form :

Intravenous Injection
Strength :

100MG/10ML(10MG/ML)
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

79
2026 :

89
2027 :

101
2028 :

109
2029 :

117
2030 :

127
2031 :

132

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Penpulimab-Kcqx

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?